Vaxcyte (NASDAQ:PCVX) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald began coverage on shares of Vaxcyte (NASDAQ:PCVX) in a research note published on Tuesday morning, MarketBeat Ratings reports. The firm issued an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Vaxcyte’s FY2025 earnings at ($5.10) EPS.

A number of other analysts have also issued reports on PCVX. The Goldman Sachs Group decreased their target price on shares of Vaxcyte from $138.00 to $100.00 and set a “buy” rating on the stock in a research report on Tuesday, April 1st. Evercore ISI upgraded shares of Vaxcyte to a “strong-buy” rating in a report on Monday, March 31st. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price target on shares of Vaxcyte in a research note on Tuesday, April 8th. Bank of America dropped their price objective on Vaxcyte from $157.00 to $137.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st. Finally, Guggenheim reissued a “buy” rating and set a $160.00 target price on shares of Vaxcyte in a report on Wednesday, March 12th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Vaxcyte presently has an average rating of “Buy” and a consensus price target of $136.50.

Vaxcyte Trading Up 4.1 %

Shares of PCVX opened at $34.51 on Tuesday. The firm’s fifty day simple moving average is $56.56 and its 200-day simple moving average is $80.88. The firm has a market capitalization of $4.45 billion, a price-to-earnings ratio of -7.50 and a beta of 1.26. Vaxcyte has a twelve month low of $27.66 and a twelve month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.14. On average, analysts predict that Vaxcyte will post -4.21 earnings per share for the current fiscal year.

Insider Transactions at Vaxcyte

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the business’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $86.22, for a total transaction of $689,760.00. Following the sale, the chief operating officer now directly owns 205,695 shares of the company’s stock, valued at $17,735,022.90. The trade was a 3.74 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 24,000 shares of company stock valued at $1,946,720 over the last three months. Company insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Vaxcyte

A number of hedge funds have recently added to or reduced their stakes in PCVX. Vanguard Group Inc. lifted its holdings in shares of Vaxcyte by 4.6% during the fourth quarter. Vanguard Group Inc. now owns 11,961,687 shares of the company’s stock worth $979,184,000 after buying an additional 521,204 shares during the last quarter. Capital Research Global Investors grew its holdings in shares of Vaxcyte by 26.8% in the 4th quarter. Capital Research Global Investors now owns 6,210,523 shares of the company’s stock worth $508,393,000 after purchasing an additional 1,312,302 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Vaxcyte by 3.0% during the 4th quarter. Franklin Resources Inc. now owns 2,869,332 shares of the company’s stock worth $234,884,000 after purchasing an additional 82,997 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Vaxcyte by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 2,802,888 shares of the company’s stock valued at $229,495,000 after purchasing an additional 102,106 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its position in Vaxcyte by 8.1% in the fourth quarter. Alliancebernstein L.P. now owns 1,779,362 shares of the company’s stock valued at $145,659,000 after buying an additional 133,448 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.